LPG restrictions threaten pharma manufacturing
OMCs began allocating 20% of the average monthly commercial LPG requirement to commercial users in March 2026.
The move aims to protect household access during global gas tensions but related LPG curbs and broader LPG/LNG supply disruptions have been reported to disrupt pharmaceutical and medical device manufacturing, affecting production of certain medicines and hospital consumables.
Isopropyl alcohol, a key chemical, is facing shortages
With refineries forced to prioritize LPG, a key chemical (isopropyl alcohol) used for making essential medicines is facing shortages, putting production of various essential medicines at risk.
Medical device companies are also hurting: less polypropylene means fewer syringes and IV sets, while higher costs and tricky GST (Goods and Services Tax) rules are squeezing already thin margins.
For young people counting on reliable healthcare (or anyone with family in the industry), these disruptions hit close to home.